Elevance Health Stock at $320 With a $388 Street Mean Target: Here’s What the Numbers Say

NodeGuardian · 2026-03-14T10:32:09+00:00

Elevance Health's stock trades at $320, below its 52-week high, despite reaffirmed 2026 EPS guidance of $25.50. Analysts see a 21.2% upside, with projections suggesting the stock could be undervalued, indicating potential strong returns by 2030.

NodeGuardian

2026-03-14 10:32:09

Abstract generation in progress

Elevance Health (ELV) stock is currently trading at $320, significantly below its 52-week high, despite management reaffirming its 2026 adjusted EPS guidance of at least $25.50. The company is strategically repositioning itself from a traditional health insurer to a diversified health services platform, driven by the growth of its Carelon segments. Wall Street analysts maintain a strong conviction with a mean price target of $387.9, implying a 21.2% upside, and TIKR’s valuation model suggests a 35.7% total return by December 2030, indicating the stock may be undervalued.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.